Asthma Clinical Trials in Boston, Massachusetts

9 studies are recruiting for asthma in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

   To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.

   Stage

   Phase 3

   Ages

   5 to 11

   Site

   Research Site, Boston, Massachusetts

   Locations

   147 in total

   Run by

   AstraZeneca

   See if you can join NCT06023589 on ClinicalTrials.gov

2. A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

   The primary objective of the trial is to evaluate the efficacy of fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electronic module (Fp/ABS eMDPI). Secondary objectives are: * To evaluate the efficacy of Fp/ABS eMDPI administered four times daily * To evaluate the safety …

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Teva Investigational Site 12119, Boston, Massachusetts

   Locations

   189 in total

   Run by

   Teva Branded Pharmaceutical Products R&D LLC

   See if you can join NCT06664619 on ClinicalTrials.gov

3. A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

   The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with asthma.

   Stage

   Phase 2

   Ages

   4 to 11

   Site

   Research Site, Boston, Massachusetts

   Locations

   43 in total

   Run by

   AstraZeneca

   See if you can join NCT07525375 on ClinicalTrials.gov

4. Registry of Asthma Characterization and Recruitment 3 (RACR3)

   This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies.

   Stage

   Not phased

   Ages

   Any age

   Site

   Boston Children's Hospital: Department of Immunology, Boston, Massachusetts

   Locations

   7 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT05272241 on ClinicalTrials.gov

5. A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

   The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   121 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07219173 on ClinicalTrials.gov

6. Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

   The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of a…

   Stage

   Phase 3

   Ages

   12 to 17

   Site

   Research Site, Boston, Massachusetts

   Locations

   150 in total

   Run by

   AstraZeneca

   See if you can join NCT06307665 on ClinicalTrials.gov

7. Protocol CAUSE-03 / CHEETAH

   This is a one-year longitudinal, observational study of 250 urban children and adolescents with asthma and 60 without asthma, ages 6-17 years old. Participants with asthma will require daily controller therapy with inhaled corticosteroids ICS (at least Step 2 therapy). Those without asthma cannot h…

   Stage

   Not phased

   Ages

   6 to 17

   Site

   Boston University School of Medicine: Pulmonary Center, Boston, Massachusetts

   Locations

   8 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT06136091 on ClinicalTrials.gov

8. Home Hospital for Suddenly Ill Adults

   The investigators propose a home hospital model of care that substitutes for treatment in an acute care hospital. Limited studies of the home hospital model have demonstrated that a sizeable proportion of acute care can be delivered in the home with equal quality and safety, reduced cost, and impro…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Brigham and Women's Hospital

   See if you can join NCT03524222 on ClinicalTrials.gov

9. Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation

   Asthma is a heterogeneous disorder in which multiple potential inflammatory pathways contribute to airway obstruction. The biological basis for airway inflammation is the subject of intensive investigation. This work is designed to identify airway factors that are responsible for recruiting cells a…

   Stage

   Phase 1

   Ages

   18 to 50

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Benjamin Medoff

   See if you can join NCT00595491 on ClinicalTrials.gov